Fosun Pharma (02196.HK) announced that its holding subsidiary Shanghai Henlius Biotechnology and its holding subsidiary (collectively "Henlius") recently received approval from the National Medical Products Administration for the clinical trial of HLX22 in combination with pertuzumab and chemotherapy, or in combination with trastuzumab for the treatment of HER2-expressing solid tumors. Henlius plans to conduct Phase II clinical trials of this new drug in China after meeting the requirements.

Fosun Pharma stated that the HLX22 involved in these treatment regimens is a new type of HER2-targeting monoclonal antibody licensed and subsequently independently developed by the group from AbClon, Inc., intended for the treatment of solid tumors such as gastric cancer and breast cancer.

As of October this year, Fosun Pharma has cumulatively invested approximately 0.105 billion Chinese yuan in the research and development of these treatment regimens. (js/u)

~